- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07878806
Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs (FUERTE)
Aim 3 Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs
The goal of this study is to learn whether FUERTE (Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs) can facilitate referrals of Hispanic men with prediabetes to the Diabetes Prevention Program (DPP) and support their continued engagement in the program.
The main questions it aims to answer are:
Does implementation of the FUERTE strategy increase the number of DPP-eligible Hispanic men who are referred to and enrolled in the DPP? Does implementation of the FUERTE strategy improve engagement in the DPP and result in greater improvements in weight and hemoglobin A1C among Hispanic men participating in the program?
FUERTE consists of three components:
- Information sessions for healthcare providers to increase awareness of the DPP.
- Text messages sent to DPP-eligible Hispanic men reminding them of appointments and encouraging discussions about prediabetes with healthcare providers.
- Interactive WhatsApp group messages for Hispanic men referred to the DPP, providing tailored content and discussion prompts related to each core DPP session.
Participants will:
- Complete a survey before enrolling in the DPP.
- Complete a survey after completing the DPP.
- Those participating post-implementation of FUERTE will (1) receive text-messages, reminding them of their appointments and encouraging discussions about prediabetes with providers, and (2) receive interactive group-messages, delivered through WhatsApp, to supplement the standard of care DPP with tailored topics and prompts.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The goal of this single-site pilot implementation trial is to learn if FUERTE (Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs), a multi-component implementation strategy for Federally Qualified Health Centers, can feasibly facilitate referrals of Hispanic men with prediabetes to the Diabetes Prevention Program (DPP) and support their continued engagement in the program. FUERTE consists of 3 components: Component 1, information sessions to providers, to increase awareness of the DPP; Component 2, text-messages, delivered through existing appointment notification systems, sent to DPP-eligible Hispanic men, to remind them of their appointments and encourage discussions about prediabetes with providers; and Component 3, interactive group-messages, delivered through WhatsApp, to Hispanic men referred to the DPP, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP.
The main questions it aims to answer is whether:
Primary Hypothesis: FUERTE increases the proportion of DPP-eligible Hispanic men seen by a provider who are (1) referred to a Nutritionist for management of prediabetes, and (2) enrolled in a DPP.
Secondary Hypothesis: FUERTE increases (1) the proportion of providers referring DPP-eligible men for prediabetes management, and (2) the mean number of weeks Hispanic men attend the core component of the DPP.
Researchers will compare the results of participants seen by providers post-implementation of FUERTE with those seen pre-implementation of FUERTE.
Participants will:
Complete a survey before enrolling in the DPP, and after completing the program.
Those participating post-implementation of FUERTE will (1) receive text-messages, delivered through existing appointment notification systems, reminding them of their appointments and encouraging discussions about prediabetes with providers, and (2) receive interactive group-messages, delivered through WhatsApp, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Christopher J Gonzalez, MD MS
- Numer telefonu: 646-962-5914
- E-mail: cjg7003@med.cornell.edu
Lokalizacje studiów
-
-
New York
-
New York, New York, Stany Zjednoczone, 10065
- Weill Cornell Medicine
-
Kontakt:
- Christopher J Gonzalez, MD MS
- Numer telefonu: 646-962-5914
- E-mail: cjg7003@med.cornell.edu
-
Główny śledczy:
- Christopher J Gonzalez, MD MS
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Self-reported Hispanic ethnicity and men
- At least 18 years old
- Have a body mass index (BMI) =>25 kg/m2
- Have a documented HbA1c of 5.7%-6.4% within one year
Exclusion Criteria:
- Life expectancy <12 months
- not planning to stay in the geographic area for at least 6 months
- diabetes based on an ICD-10 code in the previous 3 years
- does not speak English or Spanish
- present with a condition or abnormality (e.g., significant neurocognitive dysfunction) that in the opinion of the Investigator would compromise the ability of the patient to provide informed consent for the study activities, or the quality of the data
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: FUERTE Arm
Outside of this study, as part of their standard care, all participants will receive the Diabetes Prevention Program (DPP) and visits with the nutritionist at their site. Participants in this arm of the study will complete a survey before enrolling in the DPP, and after completing the program. Participants will receive interactive group-messages, delivered through WhatsApp, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP. |
Participants will complete a survey before enrolling in the Diabetes Prevention Program (DPP), and after completing the program. Participants will receive interactive group-messages, delivered through WhatsApp, to supplement standard of care (i.e. standard DPP) with tailored topics and prompts relating to each core session of the DPP. Participants will complete a survey before enrolling in the Diabetes Prevention Program (DPP), and after completing the program. |
|
Aktywny komparator: Standard Care
Outside of this study, as part of their standard care, all participants will receive the Diabetes Prevention Program (DPP) and visits with the nutritionist at their site. Participants in this arm of the study will complete a survey before enrolling in the DPP, and after completing the program. |
Participants will complete a survey before enrolling in the Diabetes Prevention Program (DPP), and after completing the program. |
|
Inny: Referring Providers
|
Referring Providers are assessed Pre and Post Implementation for the proportion of Providers seeing Diabetes Prevention Program (DPP) eligible men who then referred eligible men for Prediabetes Management. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
The proportion of Diabetes Prevention Program-eligible Hispanic men seen by a provider and referred to a Nutritionist for management of prediabetes
Ramy czasowe: 1 year
|
1 year
|
|
DPP Enrollment: The proportion of eligible Hispanic men enrolled in the Diabetes Prevention Program
Ramy czasowe: 1 year
|
1 year
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
|---|---|
|
Mean number of weeks attending the Core Component of the Diabetes Prevention Program, out of 16 possible
Ramy czasowe: 6 months
|
6 months
|
|
Mean change in weight (kg) from baseline at 6 months
Ramy czasowe: Baseline, 6 months
|
Baseline, 6 months
|
|
Mean change in A1C (%) from baseline at 6 months
Ramy czasowe: Baseline, 6 months
|
Baseline, 6 months
|
|
Referring Providers: The proportion of Providers referring eligible Hispanic men to the Diabetes Prevention Program
Ramy czasowe: 1 year
|
1 year
|
|
Referring Providers: The number of referrals placed by a Provider
Ramy czasowe: 1 year
|
1 year
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Christopher J Gonzalez, MD MS, Weill Medical College of Cornell University
Publikacje i pomocne linki
Publikacje ogólne
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
- Venkataramani M, Pollack CE, Yeh HC, Maruthur NM. Prevalence and Correlates of Diabetes Prevention Program Referral and Participation. Am J Prev Med. 2019 Mar;56(3):452-457. doi: 10.1016/j.amepre.2018.10.005. Epub 2019 Jan 17.
- Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC. Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotora randomized trial. Diabetes Care. 2011 Sep;34(9):1926-31. doi: 10.2337/dc10-2081. Epub 2011 Jul 20.
- Toro-Ramos T, Michaelides A, Anton M, Karim Z, Kang-Oh L, Argyrou C, Loukaidou E, Charitou MM, Sze W, Miller JD. Mobile Delivery of the Diabetes Prevention Program in People With Prediabetes: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2020 Jul 8;8(7):e17842. doi: 10.2196/17842.
- Chambers EC, Rehm CD, Correra J, Garcia LE, Marquez ME, Wylie-Rosett J, Parsons A. Factors in Placement and Enrollment of Primary Care Patients in YMCA's Diabetes Prevention Program, Bronx, New York, 2010-2015. Prev Chronic Dis. 2017 Mar 30;14:E28. doi: 10.5888/pcd14.160486.
- Ali MK, McKeever Bullard K, Imperatore G, Benoit SR, Rolka DB, Albright AL, Gregg EW. Reach and Use of Diabetes Prevention Services in the United States, 2016-2017. JAMA Netw Open. 2019 May 3;2(5):e193160. doi: 10.1001/jamanetworkopen.2019.3160.
- Joiner KL, Nam S, Whittemore R. Lifestyle interventions based on the diabetes prevention program delivered via eHealth: A systematic review and meta-analysis. Prev Med. 2017 Jul;100:194-207. doi: 10.1016/j.ypmed.2017.04.033. Epub 2017 Apr 27.
- American Diabetes Association. 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S34-S39. doi: 10.2337/dc21-S003.
- Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75. doi: 10.1016/S2213-8587(15)00291-0. Epub 2015 Sep 13.
- Zhu Y, Sidell MA, Arterburn D, Daley MF, Desai J, Fitzpatrick SL, Horberg MA, Koebnick C, McCormick E, Oshiro C, Young DR, Ferrara A. Racial/Ethnic Disparities in the Prevalence of Diabetes and Prediabetes by BMI: Patient Outcomes Research To Advance Learning (PORTAL) Multisite Cohort of Adults in the U.S. Diabetes Care. 2019 Dec;42(12):2211-2219. doi: 10.2337/dc19-0532. Epub 2019 Sep 19.
- Ely EK, Gruss SM, Luman ET, Gregg EW, Ali MK, Nhim K, Rolka DB, Albright AL. A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC's National Diabetes Prevention Program. Diabetes Care. 2017 Oct;40(10):1331-1341. doi: 10.2337/dc16-2099. Epub 2017 May 12.
- Jackson MC, Dai S, Skeete RA, Owens-Gary M, Cannon MJ, Smith BD, Jabrah R, Masalovich SE, Soler RE. An Examination of Gender Differences in the National Diabetes Prevention Program's Lifestyle Change Program. Diabetes Educ. 2020 Dec;46(6):580-586. doi: 10.1177/0145721720964585. Epub 2020 Oct 16.
- Cannon MJ, Masalovich S, Ng BP, Soler RE, Jabrah R, Ely EK, Smith BD. Retention Among Participants in the National Diabetes Prevention Program Lifestyle Change Program, 2012-2017. Diabetes Care. 2020 Sep;43(9):2042-2049. doi: 10.2337/dc19-2366. Epub 2020 Jul 2.
- Katula JA, Dressler EV, Kittel CA, Harvin LN, Almeida FA, Wilson KE, Michaud TL, Porter GC, Brito FA, Goessl CL, Jasik CB, Sweet CMC, Schwab R, Estabrooks PA. Effects of a Digital Diabetes Prevention Program: An RCT. Am J Prev Med. 2022 Apr;62(4):567-577. doi: 10.1016/j.amepre.2021.10.023. Epub 2022 Feb 10.
- Grock S, Ku JH, Kim J, Moin T. A Review of Technology-Assisted Interventions for Diabetes Prevention. Curr Diab Rep. 2017 Sep 23;17(11):107. doi: 10.1007/s11892-017-0948-2.
- Bian RR, Piatt GA, Sen A, Plegue MA, De Michele ML, Hafez D, Czuhajewski CM, Buis LR, Kaufman N, Richardson CR. The Effect of Technology-Mediated Diabetes Prevention Interventions on Weight: A Meta-Analysis. J Med Internet Res. 2017 Mar 27;19(3):e76. doi: 10.2196/jmir.4709.
- Fischer HH, Fischer IP, Pereira RI, Furniss AL, Rozwadowski JM, Moore SL, Durfee MJ, Raghunath SG, Tsai AG, Havranek EP. Text Message Support for Weight Loss in Patients With Prediabetes: A Randomized Clinical Trial. Diabetes Care. 2016 Aug;39(8):1364-70. doi: 10.2337/dc15-2137. Epub 2016 Feb 9.
- Formagini T, Gonzalez CJ, Dias J, Arredondo EM, Hekler E, O'Brien MJ. Advancing Type 2 Diabetes Prevention through Text-Messaging Interventions: A Narrative Review. Curr Diab Rep. 2024 Dec 4;25(1):9. doi: 10.1007/s11892-024-01568-w.
- O'Brien MJ, Vargas MC, Lopez A, Feliciano Y, Gregory DL, Carcamo P, Mohr L, Mohanty N, Padilla R, Ackermann RT, Persell SD, Feinglass J. Development of a novel clinical decision support tool for diabetes prevention and feasibility of its implementation in primary care. Prev Med Rep. 2022 Sep 7;29:101979. doi: 10.1016/j.pmedr.2022.101979. eCollection 2022 Oct.
- Chambers EC, Wylie-Rosett J, Blank AE, Ouziel J, Hollingsworth N, Riley RW, Selwyn PA. Increasing Referrals to a YMCA-Based Diabetes Prevention Program: Effects of Electronic Referral System Modification and Provider Education in Federally Qualified Health Centers. Prev Chronic Dis. 2015 Nov 5;12:E189. doi: 10.5888/pcd12.150294.
- Walker AF, Addala A, Sheehan E, Lal R, Haller M, Cuttriss N, Filipp S, Baer L, Gurka M, Bernier A, Figg L, Westen S, Hood K, Anez-Zabala C, Frank E, Roque X, Maizel J, Maahs D. Using Peer Power to Reduce Health Disparities: Implementation of a Diabetes Support Coach Program in Federally Qualified Health Centers. Diabetes Spectr. 2022 Summer;35(3):295-303. doi: 10.2337/dsi22-0004. Epub 2022 Aug 15.
- Miller HN, Berger MB, Askew S, Kay MC, Chisholm M, Sirdeshmukh G, Hopkins CM, Brewer A, DeVries A, Holder M, Bennett GG. Recruitment of diverse community health center patients in a pragmatic weight gain prevention trial. J Clin Transl Sci. 2022 Oct 10;7(1):e22. doi: 10.1017/cts.2022.475. eCollection 2023.
- US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Aug 24;326(8):736-743. doi: 10.1001/jama.2021.12531.
- Cheng YJ, Kanaya AM, Araneta MRG, Saydah SH, Kahn HS, Gregg EW, Fujimoto WY, Imperatore G. Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016. JAMA. 2019 Dec 24;322(24):2389-2398. doi: 10.1001/jama.2019.19365.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 26-06030420
- K23DK139410-01A1 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
All of the individual participant data collected during the trial, after deidentification.
Ramy czasowe udostępniania IPD
Immediately following publication. No end date.
Kryteria dostępu do udostępniania IPD
Anyone who wishes to access the data.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- ANALITYCZNY_KOD
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .